• 1
    Kramer L. Acute liver failure. Wien Klin Wochenschr 2004; 116: 6781.
  • 2
    Eisenhuber E, Madl C, Kramer L, et al. Prognostic factors in acute liver failure. Wien Klin Wochenschr 1998; 110: 5649.
  • 3
    Kramer L, Bauer E, Schenk P, et al. Successful treatment of refractory cerebral oedema in ecstasy/cocaine-induced fulminant hepatic failure using a new high-efficacy liver detoxification device (FPSA-Prometheus®). Wien Klin Wochenschr 2003; 115: 599603.
  • 4
    Faybik P, Hetz H, Krenn CG, et al. Liver support in fulminant liver failure after hemorrhagic shock. Wien Klin Wochenschr 2003; 115: 5958.
  • 5
    Saliba F, Camus C, Durand F, et al. Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS® in patients with fulminant and subfulminant hepatic failure. Hepatology 2008; 48 (Suppl): 377A.
  • 6
    Lahdenperä A, Koivusalo AM, Vakkuri A, Höckerstedt K, Isoniemi H. Value of albumin dialysis therapy in severe liver insufficiency. Transpl Int 2005; 17: 71723.
  • 7
    Kantola T, Koivusola AM, Höckerstedt K, Isoniemi H. The effect of molecular adsorbent recirculating system treatment on survival, native liver recovery, and need for liver transplantation in acute liver failure patients. Transpl Int 2008; 21: 85766.
  • 8
    Kantola T, Kantola T, Koivusalo AM, Höckerstedt K, Isoniemi H. Early molecular adsorbents recirculating system treatment of Amanita mushroom poisoning. Ther Apher Dial 2009; 13: 399403.
  • 9
    Camus C, Lavoué S, Gacouin A, et al. Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dialysis 2009; 13: 54955.
  • 10
    Faybik P, Hetz H, Mitterer G, et al. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 2011; 39: 2739.